# US 2016/0354331 A1 · Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellullar senescence produced by diabetis and other degenerative chronic complex diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354331 A1
- Document ID: US20160354331A1
- Status: Published application
- Kind: A1
- Application number: 15/176,422
- Filed: 2016-06-08
- Published: 2016-12-08
- Earliest claimed: 2015-06-08
- Inventors: Horacio Astudillo de la Vega
- Web page: https://patentgrep.com/patent/US20160354331A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/10: Dispersions; Emulsions
- A61K 47/02: Inorganic compounds
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to compounds of natural origin and their pharmaceutically acceptable and active mixture to decrease glucose, cholesterol, uric acid, and body fat the high levels, cytoprotection of damaged organs, activation of metabolism and cell proliferation. It is exemplified with the pharmaceutical composition comprising a pharmaceutically effective amount of the compounds of Formulation I, and its method on in vitro and in vivo systems. Formulation I and its variables can be used to treat hyperglycemia, gout, dyslipidemia, obesity, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, pre-diabetes, arrhythmias, myocardial infarction, renal and pancreatic complications, cardiovascular complications.

## Claims

### Claim 1

A method for decreasing the high levels of body fat, cholesterol, uric acid and glycemic index in animals and humans, the method comprising: administering a composition containing a pharmaceutically effective amount of amino acids glycine, arginine and cysteine, in any acceptable chemical presentation and a pharmaceutically effective amount of resveratrol or its derivatives in any acceptable chemical presentation (hydrate, ester, amide, polymorph, isomer or prodrug or combination thereof) such achieving to correct metabolic syndrome symptoms in subjects.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition applied comprises the following ratio of the biologically active components (Formulation I): 100-2,500 mg resveratrol, 3,000-7,000 mg glycine, 300-5,000 mg arginine and 200-2,500 mg cysteine.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition of the biologically active components is applied as an aqueous suspension, tablets, polymer capsules.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition is effective to reduce total serum cholesterol level in patient's blood.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition is effective to decrease the concentration of uric acid in patient's blood.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition is an effective amount to decrease the volume of plaque in patient's arteries.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition is an effective amount to decrease the amount of body fat of a patient.

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition is effective to reduce an high glucose concentration in patient's blood.

### Claim 9 (depends on 2)

The method of claim 2, wherein other amino acids are applied.

### Claim 10 (depends on 1)

The method of claim 1, wherein the disease is metabolic syndrome, atherosclerosis, obesity, diabetes, gout, or a combination thereof.

### Claim 11 (depends on 1)

The method of claim 1, wherein the composition is effective to reduce the progression severity of a disease associated with an abnormal increase level of serum cholesterol, glucose, uric acid, body fat, or a combination thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein the composition is effective to act as cytoprotective agent, metabolism and cell proliferation stimulator of damaged organs by metabolic syndrome, atherosclerosis, obesity, diabetes, aging, or a combination thereof.